New Anti-Arthritis Compounds Utilizing Oligosaccharides as a Treatment Modality for Rheumatoid arthritis
3'SL is normally present in breast milk as well as in circulation, so administration of the oligosaccharide would not cause any harm to these vulnerable populations.
3'SL would be administered to patients to reduce inflammation either as a direct agent or as an adjunct to existing therapies.
Researchers at UC San Diego have discovered that 3'-sialyllactose (3'SL) based oligosaccharides attenuate macrophage inflammation and suppress the secretion of pro-inflammatory cytokines, (IL)-1-beta and IL-6. This is based upon studies demonstrating that 3'SL exhibits anti-inflammatory effects in macrophages and alleviates paw swelling and cartilage damage in a collagen antibody-induced arthritis (CAIA) mouse model in vivo.
State Of Development Invention is in an experimental stage. In vitro efficacy in mouse and human cells has been confirmed. In vivo efficacy in mouse model has been confirmed. Intellectual Property Info A provisional patent has been submitted and the technology is available to license. Tech ID/UC Case 29069/2018-048-0 Related Cases 2018-048-0
美国
